非正规的HIV耐药性突变:需要缩小现有的差距
Seth Inzaule1, Michael R Jordan2, Joseph Fokam3
1Amsterdam Institute for Global Health and Development, and Department of Global Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
AIDS (London, England)
|March 7, 2025
概括
在目标部位之外的非正规HIV药物耐药性突变可能会导致HIV感染者治疗失败. 需要进行进一步的临床研究,以了解它们对病毒非抑制PWH管理的影响.
科学领域:
- 病毒学 病毒学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 越来越多的艾滋病毒感染者 (PWH) 经历治疗失败,但在主要目标区域没有可检测的耐药性.
- 低于最佳的坚持是常见的原因,但直接药物点外的耐药机制 (非正规耐药性) 也与此有关.
研究的目的:
- 探索非正规的HIV耐药性机制的潜在作用和临床相关性.
- 强调需要对这些机制进行进一步的研究,以改善艾滋病毒管理.
主要方法:
- 对各种类别的抗逆转录病毒药物 (INSTIs,PI,NNRTIs,NRTIs) 确定的非正规药物耐药性机制的审查.
- 讨论潜在的作用,包括恢复病毒健康,增强现有的抗性,独立的抗性和启动未来的抗性.
主要成果:
- 在多种药物类别中已经确定了非正规的耐药性机制.
- 这些机制可以独立地引起耐药性或与正规突变协同工作.
- 它们可能会恢复病毒的健康状况或引发耐药变异的出现.
结论:
- 非正规的HIV耐药性是治疗失败的一个合理因素,即使坚持治疗很好.
- 在试验中评估这些机制的临床相关性至关重要.
- 了解非正规耐药性可以指导病毒非抑制和公共卫生监测的管理.
关键词:
非正规的HIV耐药性突变相关概念视频
Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Mutations
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
Sexually Transmitted Infections
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...


